Drugs / Bevacizumab Biosimilar
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05386524 | Jun 2022 → Mar 2025 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04796025 | Sep 2021 → Aug 2023 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04670978 | Mar 2021 → Dec 2023 | — | Shandong University | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT06530251 Comparator | Sep 2024 → Jun 2026 overdue | hepatocellular carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT06860490 Background | Mar 2025 → Mar 2027 expected | hepatocellular carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06997497 Comparator | Jul 2025 → Mar 2029 expected | colon adenocarcinoma, rectum adenocarcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bevacizumab biosimilar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04670978 ↗ |
| Action | Inhibit | “anti-VEGF (Bevacizumab Biosimilar)” NCT04796025 ↗ |
| Route | Other | “intra-arterial infusion” NCT04796025 ↗ |